DoW Breast Cancer, Transformative Breast Cancer Consortium Award
Defense Health Agency Contracting Activity - DHACA
Free. Verify your email, then we send one reminder only.
- Posted
- May 4, 2026
- Amount
- Program total $35M
- Closes
- Sep 30, 2026 (in 14 days)
Similar opportunities open now
- DoW Breast Cancer, Breakthrough Award Level 3Same funderOpenDefense Health Agency Contracting Activity - DHACACloses in 14 days
- DoW Breast Cancer, Breakthrough Award Level 4Same funderOpenDefense Health Agency Contracting Activity - DHACACloses in 14 days
- DoW Ovarian Cancer, Clinical Trial AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 15 days
- DoW, Ovarian Cancer, Investigator-Initiated Research AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 15 days
- DoW, Peer Reviewed Cancer, Impact AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 19 days
Classification and identifiers
- Solicitation number
- HT942526BCRPTBCCA
- Assistance listing (CFDA)
- 12.420
Amount
Program total $35M
Who can apply
About this opportunity
Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Transformative Breast Cancer Consortium Award supports collaborations and ideas that will transform the lives of individuals with, and/or at risk for, breast cancer and will significantly accelerate progress toward ending breast cancer. Applications must propose a synergistic, highly integrated, multidisciplinary and multi-institutional consortium of leading scientists, clinicians and breast cancer consumer advocates that will address a major problem in a way that a single investigator or group could not accomplish. The consortium’s collaborative efforts must make a transformative impact in breast cancer. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justifica...